

Stability of pharmacy-prepared vancomycin and ceftazidime-fortified antibiotic eye drops and solutions in polypropylene syringes : a review

M.Carbonne, S.Henn-Ménétré, I.May acy, Brabois Hospital, Nancy University Hospital, France

Introduction

The treatment of endophtalmitis is based on eye drops instillations of fortified antibiotics and/or intraocular injections of ceftazidime and vancomycin. Hospital pharmacies have to make these ophtalmic preparations to mitigate the lack of patent medicines and store them to manage urgent requests. Numerous studies were carried out to determine the stability of these preparations.

e-mail

Objective

This work aims to analyze studies concerning the stability of eye drops and syringes for intraocular injection of ceftazidime and vancomycin

Material and Method

Researches were based on references such as *Trissel's stability of compounded formulations, Handbook on injectable drugs,* or databases like Scopus. Keys words for research were : "stability, antibiotic, fortified antibiotic, intracameral, ceftazidime, vancomycin". Various criteria were listed depending on the study: the concentration of the solution, the solvent, the conditions of storage and the stability data. The studies were classified according to a *quotation*. The highest value possible for the quotation is 15 points.

Results



Fortified ceftazidime eve-drops

Fortified vancomycin eye-drops

Concentration (mg/mL)	Dilution solvent	Contai- ner	Condition of storage	Stability	Quotation	References			
25	5% G	G	-20℃	90 days	13	Int J Pharm, 2002;234:205-212			
10	0.9% NaCl	G	-20℃	90 days	11	Hopipharm Vittel 2011			
25	0.9% NaCl	G	-20℃	30 days	11	Cornea,2010;29:8 07-11			
50	5% G	G	-20℃ +4℃	75 days 28 days	11	Cornea,2010;29:8 07-11			
50	0.9% NaCl	G	+4℃	15 days	11	Personnal study not published			
50	0.9% NaCl	G	+4℃ +25℃	21 days 15 days	10	J Pharm Clin, 1999;18:183-189			
50	0.9% NaCl	G	+4℃	30 days	9	J Pharm Clin,1999;18:48- 52			
31	WFI or atificial tears	G	-10℃ +4℃ +25℃	<mark>45 days</mark> 10 days 7 days	8	Am J Health Syst Pharm, 1998;55:1386-8			
5	5% G or 0.9% NaCl + buffer	G	+4℃ +24℃	63 days 17 days	6	Am J Hosp Pharm, 1986;43:1729- 1731			
5	WFI+ buffer	G	+4℃	56 days	6	Yakugaku Zasshi, 2001; 121:433- 439			
50	0.9% NaCl	G	+4℃	4 days	6	J Pharm Clin,1999;18,1:65- 66			
50	0.9% NaCl	G	-20℃	30 days	5	Pharm Hosp Fr, 2003;134:37-9			
Vancomycin ad	Vancomycin activity only								
50	5% G	G	+4℃ -18℃	31 days 31 days	1	Kaohsiung J Med Sci, 1999;15:80-6			
31	0.9% NaCl	G	+4℃ +25℃	28 days 7 days	2	Aust N Z J Opht, 1999;27:426-430			
50	BSS	G	+4℃	28 days	4	Acta Opht, 2009;87:555-8			
50	Artificial tears	G	+4℃ +25℃	extampo- raneous	2	Am J Health Syst Pharm, 1998; 55:463-6			

Concentration (mg/mL)	Dilution solvent	Contai- ner	Condition of storage	Stability	Quotation	References
20	0.9 % NaCl	G	+4℃ +25°C	10 days 2 days	11	Eur Hosp Pharm,2003;6:17- 23
50	citratebuffer + curator	G	+4℃ +20℃	12 days 2 days	11	Acta Pol Pharm, 2011;68:99-107
50	0.9 % NaCl	G	-20℃	75 days	11	Cornea,2010;29:80 7-11
50	artificial tears	G	+4℃ +25℃	7 days 1 day	9	J Pharm Clin Ther, 1999;24:299-302
20	0.9 % NaCl	G	+4℃	21 days	9	J Pharm Clin, 1999;18:48-52
50	0.9 % NaCl	G	+4℃	4 days	6	J Pharm Clin, 1999;18,1:65-66
-	WFI	G	+4℃	7 days	6	J Pharm Biomed Anal;1999,20:521- 30
30-60	WFI	G	+4℃ -20℃	10 days 30 days	4	Am J Hosp Pharm, 1992;49:2761-4
50	0.9 % NaCl	G	-20℃	30 days	NQ	Pharm Hosp Fr, 2003;134:37-9
Ceftazidime activity only						
10	WFI + buffer	G	+4℃ +20℃	30 days 14 days	4	Acta Pol Pharm,2006;63:507 -13
50	BSS	G	+4℃ +20℃	7 days 3 days	4	Acta Opht, 2009;87:555-8



Freezing solutions used within 48 hours if preserved in the fridge. Defrosting can be made at room temperature or in microwave for eye drops solutions.



Ceftazidime injectable solutions

antibiotic.

n injectable solutions						(mg/mL)	solve
lution Ivent	Contai- ner	Condition of storage	Stability	Quotation	References	20	0.9%
6 G or 9% NaCl	PVC	+4℃	14 days	12	Am J Health Syst Pharm, 1995:52:2560-4	22,5	BSS
9% NaCl	EVA	+25℃ +4℃	7 days 30 days	12	Hosp Pharm, 2001;36:1170-1173	100	WEI
9% NaCl	PP	+4℃	99 days	11	Personnal study not published	40	5% 0 0.9%
SS	PP	-18℃	180 days	10	Poster HUG, EAHP 2007/ntp:/jpharmacis.hug- ge.chirdiposters.html	40	5% (0.9%
9% NaCl 5% G WFI	PP	+4℃ +25℃	84 days 29 days	4	J Clin Pharm Ther, 1994;20:319-325	60	WFI
6 G	PP	+4℃	1 day	3	Am J Hosp Pharm,	30-60	WFI

AK

(mg/mL)	solvent	ner	of storage	Stability	quotation	Transferrences
20	0.9% NaCl	PP	4℃	10 days	11	Eur Hosp Pharm, 2003;6:17-23
22,5	BSS	PP	-18℃	180 days	10	Poster HUG,EAHP 2007 http://pharmacie.hug- ge.ch/rd/posters.html
100	WFI	PP	-20℃ +4℃	90 days 10 days	9	Am J Hosp Pharm, 1992; 49:2954-6
40	5% G or 0.9% NaCl	PVC	+4℃	7 days	8	Can J Hosp Pharm, 1988:2;65,71
40	5% G or 0.9% NaCl	PVC	-10℃ +4℃	90 days 21 days	6	J ClinPharmTher, 1988;13:199-205
60	WFI	PVC	-20℃	14 days	6	Am J Health-Syst Pharm, 1996;53:1302-5
30-60	WFI	PVC	+4℃ -20℃	10 days 30 days	4	Am J Hosp Pharm, 1992;49:2761-4

0.9% NaCl : 0.9% sodium chloride 5% G : 5% glucose WFI : water for injections BSS : balanced salt solution

PP : polypropylene_PVC : polyvinyl chloride_PE : polyethylene_G : glass_EVA : e

Discussion

Arsene M et al. (J.Pharm.Clin,2002; 27:205-209) state that ceftazidime stability at 40 mg/mL at 20°C is better in the glass container than PP container, and this stability is better in **PP container** than **PVC container**. We become to that broaden researches on stability ceftazidime and vancomycin solutions in other containers. Solutions in **PE container** seem to have the same stability as PVC container.

Kwok AK et al. (Invest Ophtalmol Vis Sci, 2002;43:1182-8) demonstrate that 0.9% NaCl is preferred to BSS as a dilution solvent for intravitreal injection, because precipitation in vitreous at body temperature occurs less and only free antibiotic molecules are efficien

Antibiotic activity is preserved one month in the fridge and seems preserved longer in the freezer even if no study has proven that

Conlusion

Freezing enables a long-term storage up to 4 months of the standardized hospital preparations, which makes it possible to have an important stock and takes a result to come up to the problem of urgent care. Thanks to this review the pharmacists can choose the best option, in collaboration with the medical teams (in particular for the choice of the solvent) and then optimize the therapeutic urgency.

Acknowledgements

Thanks to vichita OK who helped me to translate, Thanks to Dr. Jean Vigneron who managed me for this work

References : Trissel LA. Handbook on Injectable Drugs, 16th ed., published APhA; 2011. Lawrence A.Trissel, Trissel, Stability of compounded Formulations, 4th ed., published by APhA; 2009.

TCH044

Vancomyci Concentration D (mg/mL) 10

10

10

10

10

50

5% 0.

0.

0

B

0.

5%

17th Congress of the EAHP - 21-23 March 2012, Milan, Italy.

